Fumagillin in Amebiasis
- 1 July 1952
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 1 (4), 552-558
- https://doi.org/10.4269/ajtmh.1952.1.552
Abstract
Summary Fumagillin, orally, is active directly against E. histolytica in macaques and man. In man, at a total dosage of 100 mgm. over 12½ days, 9 of 10 cyst passers remained clear during 3 months; 50 mgm. total cleared only 4 of 10 patients. In monkeys, total dosage of 250–625 mgm./Kg. over 5 to 10 days was required to keep 12 of 19 animals cleared during 3 months. No signs nor symptoms of intolerance were noted in man. In monkeys, one showed retention of sulfobromophthalein while another had increased blood urea nitrogen after therapy. Other laboratory findings were not significant in either monkeys or man. Nonpathogenic intestinal parasites did not clear consistently in either mammalian species. There was close correlation between results in monkeys and man generally. A comparative study with untreated controls and with terramycin and thiocarbarsone treated patients was made. Fumagillin was most potent and appeared to be most active in chronic, drug refractive, intestinal amebiasis.Keywords
This publication has 3 references indexed in Scilit:
- In vitro and in vivo Studies of a New Antibiotic, Fumagillin, with Endamoeba histolytica.Experimental Biology and Medicine, 1951
- Antibiotics against Amebiasis in MacaquesThe American Journal of Tropical Medicine, 1950
- AN ANTIPHAGE AGENT ISOLATED FROM ASPERGILLUS SPJournal of Bacteriology, 1949